RESUMEN
In this study, we successfully synthesized d-α-tocopheryl polyethylene glycol 2000 succinate (TPGS2k) and prepared TPGS2k-modified poly(lactic-co-glycolic acid) nanoparticles (TPGS2k/PLGA NPs) loaded with 7-ethyl-10-hydroxycamptothecin (SN-38), designated TPGS2k/PLGA/SN-38 NPs. Characterization measurements showed that TPGS2k/PLGA/SN-38 NPs displayed flat and spheroidal particles with diameters of 80-104 nm. SN-38 was encapsulated in TPGS2k emulsified PLGA NPs with the entrapment efficiency and loading rates of SN-38 83.6 and 7.85%, respectively. SN-38 could release constantly from TPGS2k/PLGA/SN-38 NPs in vitro. TPGS2k/PLGA/SN-38 NPs induced significantly higher cytotoxicity on A549 cells and the multidrug resistance (MDR) cell line (A549/DDP cells and A549/Taxol cells) compared with free SN-38. Further studies on the mechanism of the NPs in increasing the death of MDR cells showed that following the SN-38 releasing into cytoplasm the remaining TPGS2k/PLGA NPs could reverse the P-gp mediated MDR via interfering with the structure and function of mitochondria and rather than directly inhibiting the enzymatic activity of P-gp ATPase. Therefore, TPGS2k/PLGA NPs can reduce the generation of ATP and the release of energy for the requisite of P-gp efflux transporters. The results indicated that TPGS2k/PLGA NPs could become the nanopharmaceutical materials with the capability to reversal MDR and improve anticancer effects of some chemotherapy drugs as P-gp substrates.
Asunto(s)
Antineoplásicos/química , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/instrumentación , Resistencia a Antineoplásicos , Ácido Láctico/química , Mitocondrias/efectos de los fármacos , Ácido Poliglicólico/química , Vitamina E/análogos & derivados , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Adenosina Trifosfato/metabolismo , Antineoplásicos/farmacología , Camptotecina/análogos & derivados , Camptotecina/química , Camptotecina/farmacología , Línea Celular Tumoral , Portadores de Fármacos/síntesis química , Resistencia a Múltiples Medicamentos , Humanos , Irinotecán , Mitocondrias/metabolismo , Nanopartículas/química , Polietilenglicoles/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Vitamina E/químicaRESUMEN
The aim of the present research was to explore whether food emulsifier polysorbate 80 can enhance the absorption of di-(2-ethylhexyl) phthalate (DEHP) and its possible mechanism. We established the high-performance liquid chromatography (HPLC) method for detecting DEHP and its major metabolite, mono-ethylhexyl phthalate (MEHP) in rat plasma, and then examined the toxicokinetic and bioavailability of DEHP with or without polysorbate 80 in rats. The study of its mechanism to increase the absorption of phthalates demonstrated that polysorbate 80 can induce mitochondrial dysfunction in time- and concentration-dependence manners in Caco-2 cells by reducing mitochondrial membrane potential, diminishing the production of the adenosine triphosphate, and decreasing the activity of electron transport chain. Our results indicated that food emulsifier applied in relatively high concentrations in even the most frequently consumed foods can increase the absorption of DEHP, and its role may be related to the structure and function damages of mitochondria in enterocytes.
Asunto(s)
Dietilhexil Ftalato/farmacocinética , Emulsionantes/toxicidad , Aditivos Alimentarios/toxicidad , Absorción Intestinal/efectos de los fármacos , Polisorbatos/toxicidad , Animales , Disponibilidad Biológica , Células CACO-2 , Supervivencia Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Dietilhexil Ftalato/sangre , Dietilhexil Ftalato/metabolismo , Dietilhexil Ftalato/toxicidad , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Estructura Molecular , Ratas Sprague-Dawley , ToxicocinéticaRESUMEN
The objective of the study was to evaluate the effect of hydroxypropyl-sulfobutyl-ß-cyclodextrin (HP-SBE-ßCD) on the bioavailability and intestinal absorption of edaravone, and identify its mechanism of action. We devised HP-SBE-ßCD as a carrier and modulator of P-glycoprotein (Pgp) efflux pump, and edaravone as a model drug, and prepared edaravone/HP-SBE-ßCD inclusion complex. HP-SBE-ßCD improved the water solubility and enhanced the bioavailability of edaravone by 10.3-fold in rats. Then, in situ single-pass intestinal perfusion showed that HP-SBE-ßCD had an effect of improving the permeability and inhibiting the efflux of edaravone. Furthermore, the effects of HP-SBE-ßCD on Pgp were achieved through interfering with the lipid raft and depleting the cholesterol of enterocytes membrane. From the results, we presented the novel mechanisms. First, edaravone/HP-SBE-ßCD had a lower release from the inclusion compound to protect edaravone from the low pH of the stomach. Then, HP-SBE-ßCD modulated the membrane microenvironment of intestinal absorption epithelial cells. At last, the result was that HP-SBE-ßCD enhanced the absorption of edaravone by interfering with Pgp. In conclusion, HP-SBE-ßCD improves the bioavailability of drug not only because of its enhancing water solubility of the drug, but also because it modulates the Pgp-mediated efflux from enterocytes.
Asunto(s)
Antipirina/análogos & derivados , Enterocitos/efectos de los fármacos , Enterocitos/metabolismo , Preparaciones Farmacéuticas/metabolismo , beta-Ciclodextrinas/farmacología , Algoritmos , Animales , Antipirina/farmacocinética , Área Bajo la Curva , Disponibilidad Biológica , Células CACO-2 , Rastreo Diferencial de Calorimetría , Colesterol/metabolismo , Cromatografía Líquida de Alta Presión , Edaravona , Excipientes , Humanos , Yeyuno/efectos de los fármacos , Yeyuno/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Espectroscopía de Resonancia Magnética , Microdominios de Membrana/metabolismo , Perfusión , Ratas , Ratas Sprague-Dawley , Solubilidad , Difracción de Rayos XRESUMEN
Chitosan-modified poly(lactic-co-glycolic acid) nanoparticles (CHI/PLGA NPs) loaded with 7-ethyl-10-hydroxycamptothecin (SN-38), named CHI/PLGA/SN-38 NPs, were successfully prepared using an oil-in-water (O/W) solvent evaporation method. The physicochemical properties of the novel NPs were characterized by DLS, Zeta potential, SEM, DSC, XRD, and FTIR. The encapsulation efficiency and drug loading content were 71.83 (±2.77)% and 6.79 (±0.26)%, respectively. In vitro drug release in the simulated gastric juice was lower than that in the intestinal juice. In situ single-pass intestinal perfusion (SPIP) studies indicated a dramatic improvement of drug absorption as a result of the synergistic effect between CHI and PLGA on P-glycoprotein (Pgp) inhibition. CHI/PLGA NPs showed high cellular uptake and low efflux for drugs in Caco-2 cells. The cytotoxicity studies revealed that CHI/PLGA NPs had a transient effect on the membrane integrity, but did not have an influence on cell viability. Based on the in vitro release studies, SPIP, and intracellular drug accumulation and transport investigations, we speculate rationally that CHI/PLGA NPs were mainly internalized in the form of intact NPs, thus escaping the recognition of enterocyte Pgp and avoiding efflux into the apical part of the enterocytes. After partial release of drugs inside the enterocytes, CHI/PLGA interfered with the microenvironment of Pgp and further weakened the Pgp-mediated efflux. Then, the drug-loaded NPs exited via the exocytose effect from the basal part of the enterocytes and entered the blood circulation. These results showed that CHI/PLGA NPs would be smart oral delivery carriers for antineoplastic agents that are also Pgp substrates.